1+ week, 6+ day ago   (529+ words) Bloom Healthcare, a passionate team of medical providers specializing in in-home primary care for seniors with complex health needs, today announced its acquisition of Christian Care House Calls, a... Bloom Healthcare Expands Dallas-Fort Worth Presence with Acquisition of Christian Care House…...

1+ mon, 4+ week ago   (201+ words) Agreement Grants Conba Rights for the Development and Commercialization of Cebranopadol for Pain Across Mainland China, Hong Kong, Macao and Taiwan, representing an important step in expanding the global potential of cebranopadol Under the Terms of the Agreement, Conba Will…...

2+ mon, 6+ day ago   (206+ words) The clinic will be the first of its kind in the U.S. to offer brain only PET scanning to assist in meeting the growing demand for early Alzheimer’s detection through beta-amyloid imaging, and to provide a key diagnostic imaging tool for…...

3+ mon, 3+ week ago   (142+ words) REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted... Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation REDWOOD CITY, Calif.,…...

4+ mon, 2+ week ago   (466+ words) Funds will support one of the largest interventional clinical trials of a full-spectrum microbiome product, and the largest ever to be conducted i... EnteroBiotix Secures £19m to Initiate Phase 2b Clinical Trial for Irritable Bowel Syndrome - Funds will support one of the largest…...

4+ mon, 2+ week ago   (397+ words) BEDFORD, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in May 2026. Upcoming Investor Conferences: Bank of America Health…...

4+ mon, 2+ week ago   (349+ words) SOL-X long-term extension trial in wet AMD enrolled the first subject in April 2026 who had successfully completed the two-year SOL-1 trial Subjects who have completed the two-year follow-up in either SOL-1 or SOL-R have an opportunity to enroll in the…...

4+ mon, 2+ week ago   (388+ words) The study treatment period will last for four weeks. PET scans will assess intestinal copper absorption by measuring the amount of 64Cu in the liver and the primary endpoint is the change in mean hepatic 64Cu standard uptake value from pre- to…...

4+ mon, 2+ week ago   (441+ words) Pre-randomization Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) set-up data from the MODERATO II randomized, prospective, multi-ce... Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026 - Pre-randomization Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) set-up data from the MODERATO…...

4+ mon, 2+ week ago   (296+ words) PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medical naïve and previously treated patients with acromegaly Crinetics’ first…...